common side effects of symbyax
asthenia
drowsiness
edema
eyelid edema
facial edema
facial swelling
hypersomnia
serum alanine aminotransferase
serum aspartate aminotransferase
joint swelling
lethargy
localized edema
periorbital edema
peripheral edema
sedation
swelling of eye
weight gain
hyperprolactinemia
serum prolactin
serum triglycerides
anasarca
appetite
xerostomia
other side effects
abnormal hepatic function tests
abnormality in thinking
diarrhea
gamma-glutamyl transferase
liver enzymes
serum transaminases
pharyngitis
tremor
amblyopia
comprehensive list of adverse effects
needed effects
fluoxetine
olanzapine
unwanted side effects
medical attention
following side effects
taking fluoxetine
olanzapine
check
doctor
fluoxetine
olanzapine side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
reported side effects
fluoxetine-olanzapine treatment in short-term controlled studies at an incidence
placebo
disturbance in attention
dry mouth
fatigue
hypersomnia
appetite
peripheral edema
sedation
somnolence
tremor
vision
weight
significant differences in the incidence of weight gain
prolactin elevation
fatigue
dizziness
week
fixed dose study
comparing mg
mg
mg olanzapine in patients with schizophrenia
schizoaffective disorder
side effects
treatment discontinuation
increased weight
sedation
week
placebo-controlled clinical trial of fluoxetine-olanzapine for the treatment of bipolar
depression in patients
years
side effects
discontinuation
incidence
placebo group
increased weight
suicidal ideation
bipolar disorder
somnolence
antidepressants
role
inducing worsening of depression
emergence of suicidality in certain patients during the early phases of treatment
increased risk of suicidal thinking
behavior in children
adolescents
young adults
years
major depressive disorder
mdd
other psychiatric disorders
short-term use of antidepressant drugs
adult
pediatric patients
receiving antidepressants for mdd
nonpsychiatric indications
reported symptoms
precursors
emerging suicidality
including anxiety
agitation
panic attacks
insomnia
irritability
hostility
aggressiveness
impulsivity
akathisia
hypomania
mania
causality
placebo-controlled clinical trials in elderly patients with dementia-related psychosis
increased risk of death in olanzapine-treated patients
placebo-treated patients
anxiety
restlessness
suicidal ideation
treatment-emergent side effect in an
week
placebo-controlled clinical trial in pediatric bipolar
depression in patients
years
nervousness
restlessness
thinking
depersonalization
emotional lability
euphoria rare
withdrawal syndromefrequency
bruxism
violent behaviors
somnolence common
disturbance in attention
taste perversion
tremor
ataxia
coma
dysarthria
hypokinesia
movement disorder
myoclonusrare
hyperkinesiafrequency
dystonias
headache
dystonias
first few days of treatment
males
younger age groups
greater risk for acute dystonia
frequency
severity of symptoms
high potency
higher doses of first generation
antipsychotic drugs
low doses
retrospective study of outpatients with parkinson
disease
mg of fluoxetine
day
patients
worsening of parkinsonism
patients
improvement of parkinsonism
patients
change
small study
series
patients
worsening of parkinsonism during treatment with fluoxetine
life-threatening serotonin syndrome
ssris
snris as monotherapy
concomitant use of other serotonergic drugs
drugs
metabolism of serotonin
neuroleptic malignant syndrome
nms
fatal symptom complex
connection
treatment with antipsychotic drugs
including olanzapine
number of case reports
implicated fluoxetine
causing seizures
patients
convulsions during pre-marketing testing
case of dose-dependent exacerbation
preexisting
mild restless legs syndrome
discontinuation of fluoxetine
somnolence
tremor
treatment-emergent side effect in an
week
placebo-controlled clinical trial in pediatric bipolar
depression in patients
years
numerous cases of hyponatremia
been reported following treatment with an ssri
risk factors for the development of ssri
associated hyponatremia
advanced age
female gender
concomitant use of diuretics
low body weight
lower baseline serum sodium levels
hyponatremia
first few weeks of treatment
range
days
weeks
range hours
weeks
therapy
patients
requiring treatment
proposed mechanism for the development of hyponatremia
siadh via release of antidiuretic hormone
hyperglycemia
olanzapine
combination with fluoxetine
analysis of controlled clinical studies
placebo
treatment duration
weeks
fluoxetine-olanzapine
greater mean change in random glucose
placebo
mg/dl
mg/dl
difference in mean changes
patients with evidence of glucose dysregulation at baseline
epidemiological studies
increased risk of treatment-emergent hyperglycemia in patients
atypical antipsychotics
association between atypical antipsychotic therapy
glucose levels
olanzapine than some other atypical antipsychotic agents
elevated uric acid
low albumin
low bicarbonate
low inorganic phosphorus
significant greater frequency in the fluoxetine-olanzapine group
placebo group in adult clinical studies
meaningful increases in total cholesterol
triglyceride levels
mg/dl
adults
significant weight gain across all baseline bmi categories
clinical trials with fluoxetine-olanzapine
analysis of controlled clinical studies
median exposure
weeks
patients
fluoxetine-olanzapine
baseline weight
long-term studies with fluoxetine-olanzapine
n =-rrb-
patients
combination
least weeks
mean weight gain of kg
increased weight
appetite
blood triglycerides
cholesterol
treatment-emergent side effects in an week
placebo-controlled clinical trial in pediatric bipolar
depression in patients
years
high fasting total cholesterol
high fasting ldl cholesterol
high fasting triglycerides
significant greater frequencies in the fluoxetine-olanzapine group
placebo group
high fasting ldl cholesterol
high fasting triglycerides
high fasting
total cholesterol
low bicarbonate
appetite
weightcommon
elevated uric acid
low albumin
low inorganic phosphorus
weight lossrare
goutfrequency
hyperglycemia
creatine phosphokinase
random triglyceride levels of mg/dl
mean standing pulse rate in patients
fluoxetine-olanzapine
beats/minute
qtcf interval prolongation of milliseconds
males
milliseconds for females
incidence
clinical trials
mean increase in qtc interval
fluoxetine-olanzapine treated patients than placebo-treated patients
fluoxetine-treated patients
mean increases in qtcf interval of milliseconds
significant greater frequency in the fluoxetine-olanzapine group
placebo group in a single
week
placebo-controlled clinical trial for bipolar
depression in children
adolescents
years
placebo-controlled study
fluoxetine
effects on intraventricular conduction
other case reports
fluoxetine
dysrhythmias
other conflicting case reports
fluoxetine
propensity
vasoconstriction
several cases of unexpected death
initiation of fluoxetine therapy
elderly patients with multiple medical problems
case report
qtc prolongation
torsades de pointes
elderly woman months
starting therapy with fluoxetine mg
qtc interval
normal following discontinuation of fluoxetine
additional cases
suggesting fluoxetine-associated qtc prolongation
torsades de pointes
edemacommon
generalized edema
vasodilatationfrequency
bradycardia
hypotension
orthostatic hypotension
tachycardia postmarketing reports
deep vein thrombosis
accidental overdose
treatment-emergent side effect in an
week
placebo-controlled clinical trial in pediatric bipolar
depression in patients
years
fatiguecommon
asthenia
chills
neck rigidity
pain
pyrexiarare
deathfrequency
body temperature dysregulation
breast pain
erectile dysfunction
menorrhagia
urinary frequency
urinary incontinenceuncommon
amenorrhea
female lactation
hypomenorrhea
metrorrhagia
urinary retention
urinary urgency
impaired urinationrare
breast engorgement
libidofrequency
abnormal ejaculation
anorgasmia
libido
dysuria
gynecological bleeding
urinary retention
galactorrhea
other ssris
estimates of the incidence of untoward sexual experience
performance
actual incidence
patients
physicians
issue
placebo-controlled clinical trials ejaculation disorder
ejaculation delay
treatment-emergent side effect at an incidence
incidence in placebo-treated male patients
dysmenorrhea
treatment-emergent side effect in an
week
placebo-controlled clinical trial in pediatric bipolar
depression in patients
years
ecchymosisuncommon
alopecia
dry skin
pruritusrare
exfoliative dermatitis
purpura frequency
erythema multiforme
sweating
fluoxetine-treated patients
skin reaction
elevated prolactinfrequency
diabetic coma
elevated prolactin levels
significant greater frequency in the fluoxetine-olanzapine group
placebo group in adult clinical studies
week
placebo-controlled clinical trial for bipolar
depression in children
adolescents
years
study
antidepressant users
reported times
upper gi bleeding episodes with the use of ssris
population
antidepressant medications
upper
gastrointestinal tract bleeding
times
patients
receiving fluoxetine
dyspepsia
treatment-emergent side effect in an
week
placebo-controlled clinical trial in pediatric bipolar
depression in patients
years
dry mouthcommon
abdominal distension
diarrhea
flatulenceuncommon
buccoglossal syndrome
gastritis
gastroenteritis
nausea
vomiting
peptic ulcer rare
gastrointestinal hemorrhage
intestinal obstruction
pancreatitisfrequency
esophageal ulcer
low hemoglobin
low lymphocytesuncommon
anemia
thrombocytopeniarare
leukopeniafrequency
aplastic anemia
neutropenia
low lymphocytes
low hemoglobin
significant greater frequency in the fluoxetine-olanzapine group
placebo group in adult clinical studies
alt levels
decreasing
last follow-up in the majority of patients
discontinued treatment with fluoxetine-olanzapine
low total bilirubin levels
significant greater frequency in the fluoxetine-olanzapine group
placebo group in adult clinical studies
elevated alt
ast levels
significant greater frequencies in the fluoxetine-olanzapine group
placebo group in a single
week
placebo-controlled clinical trial for bipolar
depression in children
adolescents
years
elevated alt
ast
low total bilirubincommon
significant alt elevation
times
upper limit of normal
uln
alt elevations times
uln
bilirubinemia
liver fatty depositfrequency
cholestatic jaundice
alkaline phosphatase
jaundice postmarketing reports
mixed liver injury
hepatitis
photosensitivity reaction
arthralgia
musculoskeletal stiffness
pain in extremity
osteoporosispostmarketing reports
rhabdomyolysis
epidemiological studies
patients
aged years
increased risk of bone fractures in patients
receiving ssris
tcas
pain
treatment-emergent side effect in an
week
placebo-controlled clinical trial in pediatric bipolar
depression in patients
years
eye disordersuncommon
abnormality of accommodation
dry eyes
elevated urea nitrogen levels
significant greater frequency in the fluoxetine-olanzapine group
placebo group in adult clinical studies
glycosuria
incidence
patients
fluoxetine-olanzapine in an analysis of controlled clinical studies
placebo group
elevated urea nitrogen
glycosuriarare
increased creatinine
sinusitisuncommon
epistaxis
yawnrare
laryngismusfrequency
eosinophilic pneumoniapostmarketing reports
pulmonary embolism
side effects of symbyax
fda
healthcare professional for medical advice
bloating
swelling of the face
arms
hands
lower legs
feet
body aches
pain
confusion
congestion
cough
delusions
dementia
dryness
soreness of the throat
fever
hoarseness
rapid weight gain
runny nose
shakiness in the legs
arms
hands
feet
tender
swollen glands in the neck
tingling of the hands
feet
trembling
shaking of the hands
feet
trouble with swallowing
unusual weight gain
loss
voice changes
blurred vision
change in personality
change in vision
breathing
difficulty with sleeping
difficulty with speaking
dizziness
ear pain
headache
impaired vision
increase in body movements
loss of memory
nervousness
pounding in the ears
problems with memory
pounding
irregular heartbeat
pulse
tightness in the chest
inability
eyes
spasms of the eyelid
sticking
tongue
uncontrolled twisting movements of the neck
trunk
arms
legs
unusual facial expressions
tarry stools
constipation
severe stomach pain
vomiting of blood
material
coffee grounds
diarrhea
dry mouth
increased appetite
lack
loss of strength
weight gain
change
problem with discharge of semen
decreased interest in sexual intercourse
difficulty with moving
inability
erection
loss in sexual ability
desire
drive
performance
muscle pain
stiffness
orgasm
pain
swelling
redness in the joints
tooth disorder
twitching